Market Overview
According to the DataM market research report, the global cervical cancer diagnostics market reached USD 8,042.9 million in 2022 and is projected to witness lucrative growth by reaching up to USD 13,022.1 million by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030).
Increasing product approvals, changes in lifestyle, rising incidences of cardiovascular diseases, favorable reimbursement policies, and government funding initiatives will propel the global cervical cancer diagnostics market over the forecast period.
Cervical cancer affects the cells in the cervix and can be diagnosed through tests such as a Pap smear, colposcopy, and ECC. The market for cervical cancer diagnosis is expected to grow due to rising awareness and increasing prevalence in emerging economies. The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, and region. North America is anticipated to hold approximately 38.9% of the global cervical cancer diagnostics market due to the region’s increasing market developments and expanding awareness.
The major global players in the market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics, Olympus, Cardinal Health, Siemens Healthcare, Hologic, Inc., Quest Diagnostics, QIAGEN, OncoHealth Corp., Arbor Vita, Zilico Ltd., and among others.
Market Drivers
The rising incidence of cervical cancer worldwide is propelling the growth of the cervical cancer diagnostics market over the forecast period. In the United States in 2023, the American Cancer Society estimates that there will be over 13,960 new cases of invasive cervical cancer and approximately 4,310 deaths due to cervical cancer. The increasing number of product approvals for cervical cancer diagnostics by distinct regulatory bodies is driving the global cervical cancer diagnostics market growth during the forecast period.
Market Restraints
False-positive tests are screening tests that return a positive result but are not subsequently validated with high-grade cervical intraepithelial neoplasia (CIN). Increasing false positive results are impeding the growth of the global market for cervical cancer diagnostics over the forecast period. In one study, the lifetime probability of a false positive for annual, 3-year, and 5-year triage testing (either LBC with HPV reflex or vice versa) was 35.1%, 13.4%, and 8.2%, respectively.
Market Opportunities
There is a growing emphasis on cervical cancer prevention through awareness campaigns and screening programs. Opportunities exist for businesses to develop and market innovative diagnostic solutions that can improve screening accuracy, accessibility, and convenience. This includes developing point-of-care testing devices, self-sampling kits, and telemedicine-based screening solutions.
For more details on this report Request for Sample: https://www.datamintelligence.com/download-sample/cervical-cancer-diagnostics-market
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict has significantly impacted the global market for cervical cancer diagnostics. Since the conflict in Ukraine has evolved into a full-blown humanitarian catastrophe. Continued hostilities endanger the lives of civilians and cause severe damage to housing, water and electrical reserves, heating, and public institutions such as schools and hospitals. Millions of individuals lack access to basic necessities.
Thus, the EU has mobilized all possible aid to assist the Ukrainian crisis service. Due to the urgent need for crisis equipment in Ukraine, the EU has deployed services from its medical rescue reserves, including generators, medical equipment, temporary shelter units, and technical tools for threats to public health, such as biological, chemical, radiological, and nuclear hazards.
Artificial Intelligence (AI) Impact Analysis
In the future, the expanding use of artificial intelligence in product development will positively affect the global cervical cancer diagnostics market. In August of 2022, Microsoft and SRL Diagnostics created an instrument based on artificial intelligence to aid in quicker cervical cancer diagnosis.
Recent Developments in the Industry
- In February 2023, BD and Company (Becton, Dickinson, and Company), an American multinational medical technology corporation, received U.S. Food and Drug Administration (FDA) approval for its product, the BD onclarity HPV Assay to be utilized with the ThinPrep Pap Test.
- In January 2022, SANSURE BIOTECH INC., an in-vitro diagnostic developments supplier, declared that its HPV DNA Diagnostic Kit (HPV 13+2)’ was authorized by the China National Medical Products Administration (NMPA).
- In November 2021, Hologic, Inc., a medical technology corporation primarily concentrating on women’s health, revealed its new ‘Genius Digital Diagnostics System,’ commercially obtainable in Europe.
Market Segmentation
As per the research analysis, the global cervical cancer diagnostics market is segmented by test type into pap smear test, HPV DNA test, coloscopy, ECC test, and others; by age group into below 21, 21-29, 30-65, 65 and above; and by distribution channel into hospital pharmacies, retail pharmacies, and e-commerce.
- Based on the test type, the HPV DNA Test type segment is estimated to hold about 27.6% of the global cervical cancer diagnostics market owing to the increasing product developments. For instance, in March 2022, the Department of Chemistry, Faculty of Science, Chulalongkorn University’s research team in Thailand, have developed a urine HPV paper-based DNA sensor testing kit for cervical cancer that would permit an easy and pain-free approach that can be performed repeatedly.
View Full Report: https://www.datamintelligence.com/research-report/cervical-cancer-diagnostics-market
Geographical Analysis
The global cervical cancer diagnostics market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Cervical Cancer Diagnostics Market:
North America is anticipated to hold approximately 38.9% of the global cervical cancer diagnostics market due to the region’s increasing market developments and expanding awareness. For instance, January has been established as “Cervical Health Awareness Month” by the United States Congress. The National Cervical Cancer Coalition (NCCC) and its multiple local chapters all over the nation increase awareness regarding cervical cancer, HPV disease, and the significance of earlier diagnosis during the month of January. While NCCC branches host occasions throughout the year, Cervical Health Awareness Month is observed in January, and branches perform to increase community awareness.
Competitive Landscape
The major global players in the market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics, Olympus, Cardinal Health, Siemens Healthcare, Hologic, Inc., Quest Diagnostics, QIAGEN, OncoHealth Corp., Arbor Vita, Zilico Ltd., and among others.
Related Reports
Multiplexed Diagnostics Market
Chlamydia Infection Diagnostics Market
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query with regard to the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights:
- The report offers a comprehensive evaluation of the market in terms of market value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2021-2022), and verifiable projections about market size during the forecast period (2023-2030).
- Visualize the composition of the global cervical cancer diagnostics market segmentation by test type, age group, distribution channel, and region, highlighting the key commercial assets and players.
- By Test Type: Pap Smear Test, HPV DNA Test, Coloscopy, ECC Test, Others
- By Age Group: Below 21, 21-29, 30-65, 65 and above
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and E-Commerce.
- By Region: North America, South America, Europe, Asia Pacific, Middle East & Africa
- Identify commercial opportunities in the global cervical cancer diagnostics market by analyzing trends and co-development deals.
- The report also covers data insights on various industry forces such as Porter’s five forces analysis, supply chain analysis, pricing analysis, regulatory analysis.
- Excel data sheet with thousands of data points of global cervical cancer diagnostics market -level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in Excel for the key product of all major market players
The report will provide access to approximately 61 market data tables, 64 figures and close to 180 pages.
About Us:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.